A heterologous vaccine regimen consisting of a first dose of the AstraZeneca vaccine and a second dose of the Pfizer vaccine induces a stronger immune response than a regimen consisting of two doses of the AstraZeneca vaccine.
Vincent, Kathy and Rich explain the Jenner Institute’s SARS-CoV-2 vaccine, the NIH decision to stop the Remdesivir study, and answer listener questions. Click arrow to play Download TWiV 613 (63 MB .mp3, 106 min) Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
